Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Dis

Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Disease
 Milestone Marks Swiss Company’s Entrance into the U.S. Blood Coagulation Market
HOBOKEN, N.J., Dec. 7 /PRNewswire/ — Octapharma USA today announced the U.S. Food and Drug Administration has approved wilate® for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease (VWD). Wilate® is a newly developed, high-purity, double virus inactivated von Willebrand Factor/Coagulation Factor VIII Concentrate (Human) that demonstrated efficacy for all types of VWD, including pediatric patients, in four prospective clinical trials utilizing both objective and subjective criteria.
Read more: http://www.fiercebiotech.com/press-releases/octapharma-usa-announces-fda-approval-wilate-r-first-replacement-therapy-developed–0#ixzz0Z91XnDO3